Full video transcriptClick to expand
Auto-generated transcript of @justinnaultofficial's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Ozempic is killing people. The company making billions knew that it was coming.
- 0:03I'm going to show you how Big Pharma turned a diabetes drug into a $26 billion death trap.
- 0:08In 2017, the FDA approved Ozempic for diabetes.
- 0:11Novo Nordisk saw something else. Wait loss. They didn't run major new safety trials for obesity
- 0:16patients. They just rebranded the drug at higher doses.
- 0:18Long Shwegove in June 2021. Novo Nordisk makes $26 billion from Ozempic and Wagove combined.
- 0:24$14.6 billion in pure profit.
- 0:27A revenue grew 26% in just one year while Americans were dying.
- 0:31FDA's own database shows 162 deaths linked to these drugs.
- 0:35That number jumped 40% in just six months.
- 0:37For 62,000 adverse events reported,
- 0:39over 10,000 of them serious enough to require hospitalization.
- 0:43Stomach paralysis so severe that people can't eat.
- 0:45Intestinal blockages requiring emergency surgery.
- 0:48Fatal pancreatitis, permanent blindness from sudden optic nerve death.
- 0:52Kidney failure from severe vomit. 1800 lawsuits have been filed.
- 0:56Patients claiming that Novo Nordisk buried the risks.
- 0:58Studies show you regain two thirds of the lost weight within a year of stopping the drug.
- 1:02So you stay on it forever.
- 1:03$1,000 per month to have your stomach slowly die.
- 1:0637% of people with Ozempic complications required hospitalization.
- 1:1012% of all Americans have tried these drugs.
- 1:12That's 40 million people rolling the dice on permanent injury.
- 1:16All because you've been lied to about weight loss.
- 1:18You're not struggling to lose weight because you lack willpower or have some obesity gene.
- 1:22You're struggling because your metabolism is broken because it's been poisoned by ultra-processed food.
Ozempic side effect claims on TikTok: hype vs. hard data
Quick answer
Semaglutide (Ozempic, Wegovy) carries FDA label warnings for gastroparesis risk, acute pancreatitis, and potential thyroid C-cell tumor risk based on rodent studies, with post-market surveillance continuing to identify gastrointestinal serious adverse events. The STEP trials established Wegovy's efficacy and safety profile in non-diabetic adults with obesity, but long-term cardiovascular and renal outcome data in that population is still maturing. Clinicians should weigh these documented risks against patient-specific cardiometabolic risk burden, as the SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major cardiovascular events in overweight or obese adults without diabetes.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic side effect claims on TikTok: hype vs. hard data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic side effect claims on TikTok: hype vs. hard data" from Justin Nault. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic, Wegovy) carries FDA label warnings for gastroparesis risk, acute pancreatitis, and potential thyroid C-cell tumor risk based on rodent studies, with post-market surveillance continuing to identify gastrointestinal serious adverse events.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic wasn t made for weight loss but now it s a 26b busin." In this clip, the useful excerpt is: "Ozempic is killing people." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide (Ozempic, Wegovy) carries FDA label warnings for gastroparesis risk, acute pancreatitis, and potential thyroid C-cell tumor risk based on rodent studies, with post-market surveillance continuing to identify gastrointestinal serious adverse events.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide (Ozempic, Wegovy) carries FDA label warnings for gastroparesis risk, acute pancreatitis, and potential thyroid C-cell tumor risk based on rodent studies, with post-market surveillance continuing to identify gastrointestinal serious adverse events. The STEP trials established Wegovy's efficacy and safety profile in non-diabetic adults with obesity, but long-term cardiovascular and renal outcome data in that population is still maturing. Clinicians should weigh these documented risks against patient-specific cardiometabolic risk burden, as the SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major cardiovascular events in overweight or obese adults without diabetes.
- Wegovy's FDA approval required separate Phase 3 trials (the STEP program) in non-diabetic adults with obesity, enrolling thousands of participants. The claim that no new safety trials were run is false.
- FAERS adverse event reports, including the 162 deaths cited, are unverified associations, not confirmed drug-caused outcomes. The database's own methodology page prohibits the causal interpretation the video makes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Wegovy's FDA approval required separate Phase 3 trials (the STEP program) in non-diabetic adults with obesity, enrolling thousands of participants. The claim that no new safety trials were run is false.
- FAERS adverse event reports, including the 162 deaths cited, are unverified associations, not confirmed drug-caused outcomes. The database's own methodology page prohibits the causal interpretation the video makes.
- Davies et al. (2022) confirmed that roughly two-thirds of weight lost on semaglutide returns within one year of stopping. The dependency concern the creator raises has real scientific support.
- Sodhi et al. (2023, JAMA) found a real association between GLP-1 drugs and increased gastroparesis risk compared to bupropion-naltrexone. Gastrointestinal adverse events are documented and listed on the label, not buried.
- The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major cardiovascular events by 20% in overweight adults without diabetes, a finding the video omits entirely from its risk-only framing.
- KFF 2024 polling estimated 6% of U.S. adults have used a GLP-1 drug, roughly half the 12% figure stated in the video.
- No peer-reviewed evidence currently supports the claim that ultra-processed food has 'poisoned' metabolism in a toxicological sense, though diet-related metabolic dysfunction is a legitimate and active area of research.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @justinnaultofficial actually say?
The video argues that Novo Nordisk knowingly hid deadly risks when it repurposed semaglutide from diabetes to weight loss, calling Ozempic a "$26 billion death trap" and claiming the FDA database shows 162 deaths linked to the drug. It also states that 62,000 adverse events have been reported, 12% of Americans have tried GLP-1 drugs, and that 37% of people with complications required hospitalization. The creator wraps with a metabolic theory: your weight struggles aren't your fault, they're caused by ultra-processed food poisoning your metabolism.
Some of those numbers are real. Some are pulled wildly out of context. And the framing throughout treats correlation as causation in ways that would not survive peer review.
Does the science back this up?
Partly, but not in the way the video implies. The serious adverse events are documented, but the risk profile looks very different when you put it against the size of the population using these drugs.
The FAERS database (FDA Adverse Event Reporting System) does contain reports of gastroparesis, pancreatitis, and vision problems associated with semaglutide. A 2023 study by Sodhi et al. in JAMA found that GLP-1 receptor agonists were associated with a higher risk of gastroparesis compared to bupropion-naltrexone. That is a real signal. But FAERS reports are not confirmed causal links. They are self-reported or provider-reported events that happened while someone was on a drug. The database itself carries a disclaimer the video ignores entirely.
On weight regain, the creator is actually close to correct. Davies et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained approximately two-thirds of lost weight within a year of stopping semaglutide. That finding is solid and underreported in mainstream GLP-1 coverage.
What did they get wrong (or right)?
Wrong: The claim that Novo Nordisk "didn't run major new safety trials for obesity patients" before Wegovy's approval is false. Wegovy was approved based on the STEP trial program, a series of large Phase 3 randomized controlled trials enrolling over 4,500 non-diabetic participants with obesity (Wilding et al., 2021, New England Journal of Medicine). Regulatory approval required separate efficacy and safety data. The dose is higher than Ozempic, and that difference was studied.
Wrong: "162 deaths linked to these drugs" presented as definitive. FAERS deaths are reported associations, not confirmed drug-caused fatalities. Many patients on GLP-1 drugs have obesity, type 2 diabetes, and cardiovascular disease, conditions that independently carry mortality risk. The creator presents a raw count as a body count, which is not how pharmacovigilance works.
Wrong: "12% of all Americans have tried these drugs." The actual estimate from KFF polling (2024) is around 6% of U.S. adults have used a GLP-1 drug, not 12%.
Right: The weight regain data is accurate and the dependency concern is legitimate. Right: Gastroparesis and intestinal obstruction are documented risks, listed in Wegovy's FDA prescribing information. Right: The lawsuits are real, though 1,800 at time of filming has since grown substantially.
What should you actually know?
GLP-1 receptor agonists are not consequence-free. They carry real, documented gastrointestinal risks, and the long-term data in non-diabetic populations is still accumulating. If you are considering semaglutide or tirzepatide for weight management, those conversations belong with a licensed clinician who knows your full medical history, not a TikTok video on either side of this debate.
The video's core rhetorical move is worth naming: it takes real adverse event data and strips it of denominator context. Tens of millions of prescriptions have been filled. A few thousand serious events in that context tells a different story than the same number presented in isolation. That is not a defense of the pharmaceutical industry. It is basic epidemiology.
The metabolic claims at the end, that ultra-processed food has "poisoned" your metabolism, are speculative. Research does link ultra-processed food consumption to metabolic dysfunction (Monteiro et al., 2019, Public Health Nutrition), but "poisoned" implies a reversible toxicological mechanism that the science does not currently support in those terms.
Be skeptical of anyone, including this video, who tells you the answer is simple.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Justin Nault · TikTok creator
1.4M views on this video
Ozempic wasn’t made for weight loss. But now it’s a $26B business. And people are paying for it with their health. ⚠️ Stomach paralysis ⚠️ Emergency surgeries ⚠️ Vision loss ⚠️ Kidney failure ⚠️ Over 3,600 lawsuits (and rising) You weren’t broken. You were lied to. Your metabolism didn’t fail… it was poisoned by the food system. Now instead of fixing that, we’re injecting people with a drug they can never stop… and calling it “health.” Some lose weight. Others can’t eat without pain. And no
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about wegovy's fda approval required separate phase 3 trials (the step?
Wegovy's FDA approval required separate Phase 3 trials (the STEP program) in non-diabetic adults with obesity, enrolling thousands of participants. The claim that no new safety trials were run is false.
What does the video say about faers adverse event reports, including the 162 deaths cited,?
FAERS adverse event reports, including the 162 deaths cited, are unverified associations, not confirmed drug-caused outcomes. The database's own methodology page prohibits the causal interpretation the video makes.
What does the video say about davies et al. (2022) confirmed?
Davies et al. (2022) confirmed that roughly two-thirds of weight lost on semaglutide returns within one year of stopping. The dependency concern the creator raises has real scientific support.
What does the video say about sodhi et al. (2023, jama) found a real association between?
Sodhi et al. (2023, JAMA) found a real association between GLP-1 drugs and increased gastroparesis risk compared to bupropion-naltrexone. Gastrointestinal adverse events are documented and listed on the label, not buried.
What does the video say about the select trial (lincoff et al., 2023, nejm) found semaglutide?
The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major cardiovascular events by 20% in overweight adults without diabetes, a finding the video omits entirely from its risk-only framing.
What does the video say about kff 2024 polling estimated 6% of u.s. adults have used?
KFF 2024 polling estimated 6% of U.S. adults have used a GLP-1 drug, roughly half the 12% figure stated in the video.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Justin Nault, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.